Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: The MONtelukast In Chronic Asthma (MONICA) study

Respiratory Medicine

Volumn 104, Issue 5, 2010, Pages 644-651

  Virchow, J Christian ^a   Mehta, Anish ^b   Ljungblad, Li ^c   Mitfessel, Harald ^d  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Kendle GmbH   (Germany)

^d Pneumologische Praxis   (Germany)

Author keywords

Add on therapy; Asthma therapy; Leukotriene receptor antagonist; Montelukast

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MONTELUKAST; SHORT ACTING DRUG; THEOPHYLLINE; ACETIC ACID DERIVATIVE; ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; QUINOLINE DERIVATIVE;

ADD ON THERAPY; ADULT; ANXIETY; ARTICLE; ASTHMA; BLADDER CANCER; BRONCHITIS; CLINICAL TRIAL; DISEASE CONTROL; DISEASE SEVERITY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HALLUCINATION; HUMAN; INFECTION; INFESTATION; INSOMNIA; KNEE MENISCUS RUPTURE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NIGHTMARE; OBSERVATIONAL STUDY; OPEN STUDY; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RESTLESSNESS; RHINOPHARYNGITIS; SEPTIC SHOCK; SIDE EFFECT; SKIN DISEASE; SLEEP DISORDER; STOMACH CANCER; DOSE RESPONSE; DRUG COMBINATION; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ACETATES; ADRENERGIC BETA-AGONISTS; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; QUINOLINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77951620096     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.11.022     Document Type: Article

References (26)

1. Global Initiative for Asthma (GINA) 2008. Global strategy for asthma management and prevention. http://www.ginasthma.com 2008.
2. Masoli M., Fabian D., Holt S., and Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 59 (2004) 469-478
3. Bousquet J., Jeffery P.K., Busse W.W., Johnson M., and Vignola A.M. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 161 (2000) 1720-1745
4. Nissim Ben Efraim AH. Levi-Schaffer F. Tissue remodeling and angiogenesis in asthma: the role of the eosinophil. Ther Adv Respir Dis 2 (2008) 163-171
5. Zhu J., Qiu Y.S., Figueroa D.J., Bandi V., Galczenski H., Hamada K., Guntupalli K.K., Evans J.F., and Jeffery P.K. Localization and upregulation of cysteinyl leukotriene-1 receptor in asthmatic bronchial mucosa. Am J Respir Cell Mol Biol 33 (2005) 531-540
6. Levy M.L., Thomas M., Small I., Pearce L., Pinnock H., and Stephenson P. Summary of the 2008 BTS/SIGN British Guideline on the management of asthma. Prim Care Respir J 18 Suppl. 1 (2009) S1-16
7. National Institutes of Health NHLaBINAEaPP. Expert panel report 3: guidelines for the diagnosis and management of asthma; 2007.
8. Bateman E.D., Boushey H.A., Bousquet J., Busse W.W., Clark T.J., Pauwels R.A., and Pedersen S.E. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 170 (2004) 836-844
9. Rabe K.F., Adachi M., Lai C.K., Soriano J.B., Vermeire P.A., Weiss K.B., and Weiss S.T. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol 114 (2004) 40-47
10. Blake K.V. Montelukast: data from clinical trials in the management of asthma. Ann Pharmacother 33 (1999) 1299-1314
11. Jarvis B., and Markham A. Montelukast: a review of its therapeutic potential in persistent asthma. Drugs 59 (2000) 891-928
12. Pizzichini E., Leff J.A., Reiss T.F., Hendeles L., Boulet L.P., Wei L.X., Efthimiadis A.E., Zhang J., and Hargreave F.E. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 14 (1999) 12-18
13. Reiss T.F., Sorkness C.A., Stricker W., Botto A., Busse W.W., Kundu S., and Zhang J. Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 52 (1997) 45-48
14. Williams B., Noonan G., Reiss T.F., Knorr B., Guerra J., White R., and Matz J. Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. Clin Exp Allergy 31 (2001) 845-854
15. Bjermer L., Bisgaard H., Bousquet J., Fabbri L.M., Greening A.P., Haahtela T., Holgate S.T., Picado C., Menten J., Dass S.B., Leff J.A., and Polos P.G. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 327 (2003) 891
16. Joos S., Miksch A., Szecsenyi J., Wieseler B., Grouven U., Kaiser T., and Schneider A. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax 63 (2008) 453-462
17. Price D.B., Hernandez D., Magyar P., Fiterman J., Beeh K.M., James I.G., Konstantopoulos S., Rojas R., van Noord J.A., Pons M., Gilles L., and Leff J.A. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 58 (2003) 211-216
18. Virchow Jr. J.C., Prasse A., Naya I., Summerton L., and Harris A. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med 162 (2000) 578-585
19. Dupont L., Potvin E., Korn D., Lachman A., Dramaix M., Gusman J., and Peche R. Improving asthma control in patients suboptimally controlled on inhaled steroids and long-acting beta2-agonists: addition of montelukast in an open-label pilot study. Curr Med Res Opin 21 (2005) 863-869
20. Korn D., Van den B.P., Potvin E., Dramaix M., Herbots E., and Peche R. Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open-label study. Curr Med Res Opin 25 (2009) 489-497
21. Juniper E.F., Guyatt G.H., Cox F.M., Ferrie P.J., and King D.R. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 14 (1999) 32-38
22. Vaquerizo M.J., Casan P., Castillo J., Perpina M., Sanchis J., Sobradillo V., Valencia A., Verea H., Viejo J.L., Villasante C., Gonzalez-Esteban J., and Picado C. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 58 (2003) 204-210
23. Nathan R.A., Sorkness C.A., Kosinski M., Schatz M., Li J.T., Marcus P., Murray J.J., and Pendergraft T.B. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 113 (2004) 59-65
24. Lundback B., and Dahl R. Assessment of asthma control and its impact on optimal treatment strategy. Allergy 62 (2007) 611-619
25. Price D., Ryan D., Pearce L., and Bride F. The AIR study: asthma in real life. Asthma J 4 (1999) 74-78
26. Holgate S., Bisgaard H., Bjermer L., Haahtela T., Haughney J., Horne R., McIvor A., Palkonen S., Price D.B., Thomas M., Valovirta E., and Wahn U. The Brussels Declaration: the need for change in asthma management. Eur Respir J 32 (2008) 1433-1442